Company Profile
Verve Therapeutics Stock Price, News & Analysis
- Ticker:
- VERV
- Exchange:
- NASDAQ
- Sector:
- Healthcare Services
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for VERV.
Company overview
Business overview
Verve Therapeutics is a gene-editing and cardiovascular company focused on one-time treatments for atherosclerotic disease. It tries to bring the durability of genetic medicine into heart disease.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Verve sits in advanced biotechnology.
Business Model Characteristics
The business is driven by platform validation, early clinical data, and the long-term opportunity to create a genetic cardiovascular franchise.
Position Within the Biotechnology Landscape
Verve is one of the more interesting cardiovascular gene-editing names because it could redefine how heart disease is treated.
Future catalysts
Verve Therapeutics's catalysts are its cardiovascular base-editing programs, especially the PCSK9 and LPA work, where the next human data decide whether in vivo editing is ready for prime time. The company needs a clean step forward to keep the gene-editing story credible.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Verve Therapeutics do?
Verve Therapeutics is a gene-editing and cardiovascular company focused on one-time treatments for atherosclerotic disease. It tries to bring the durability of genetic medicine into heart disease.
On which exchange is VERV stock listed?
Verve Therapeutics (VERV) is associated with NASDAQ, United States, Healthcare Services.
What is Verve?
Verve Therapeutics's catalysts are its cardiovascular base-editing programs, especially the PCSK9 and LPA work, where the next human data decide whether in vivo editing is ready for prime time.
Which conditions is Verve Therapeutics targeting with Verve?
Verve Therapeutics is associated with cardiovascular disease, genetic disease based on its company overview and current catalyst commentary.
How does Verve Therapeutics describe recent progress with Verve?
Verve Therapeutics's catalysts are its cardiovascular base-editing programs, especially the PCSK9 and LPA work, where the next human data decide whether in vivo editing is ready for prime time.
What is Therapeutics?
Verve Therapeutics is a gene-editing and cardiovascular company focused on one-time treatments for atherosclerotic disease.
What should investors watch for with Therapeutics?
Verve Therapeutics's catalysts are its cardiovascular base-editing programs, especially the PCSK9 and LPA work, where the next human data decide whether in vivo editing is ready for prime time.
What is PCSK9?
Verve Therapeutics's catalysts are its cardiovascular base-editing programs, especially the PCSK9 and LPA work, where the next human data decide whether in vivo editing is ready for prime time.